INTRODUCTION
============

Women tend to experience worse clinical outcomes than men after undergoing contemporary interventional therapies.[@B1][@B2][@B3] Poorer clinical outcomes in women may be because women have higher risk profiles for delayed onset of disease, older age, smaller body surface area, and comorbidities at the time of clinical presentation of coronary artery disease.[@B1][@B2][@B3] In addition, women reportedly exhibit higher procedural risk than men according to the National Cardiovascular Data Registry[@B4] and a lower revascularization rate of lesions with chronic total occlusion (CTO) after coronary artery bypass graft surgery, based on the Canadian Multicenter CTO Registry.[@B5] However, other studies have shown that after adjusting for confounding risk factors, sex-specific risk was limited, and adjusted rates of adverse cardiac events, including long-term mortality and revascularization, were similar between women and men.[@B1][@B2][@B3] Accordingly, although sex differences may exist in a high-risk subset of coronary artery disease patients, sex-specific clinical outcomes have not been well established, partly because of the small sample of women in prospective trials.

Compared to men, women have smaller vessels,[@B6][@B7][@B8] and a smaller target vessel size has been shown to be associated with a greater likelihood of target lesion revascularization.[@B9] Meanwhile, however, women reportedly show a similar rate of target lesion revascularization after stent implantation, compared to men, despite smaller vessel sizes.[@B1] Although differences in body size and clinical risk factors may explain this paradoxical finding, detailed associations among sex, anthropometric measurements, and procedural/clinical outcomes after percutaneous coronary intervention (PCI) have not yet been established.

In this study, we sought to investigate the effects of sex and anthropometric measurements on clinical outcomes after next-generation drug-eluting stent (DES) implantation for complex coronary lesions with long stenosis or CTO using intravascular ultrasound (IVUS).

MATERIALS AND METHODS
=====================

Study population
----------------

Patients were identified from three randomized trials: REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation (RESET),[@B10][@B11] Impact of intraVascular UltraSound guidance on outcomes of Xience Prime stents in Long lesions (IVUS-XPL),[@B12] and Chronic Total Occlusion InterVention with drUg-eluting Stents (CTO-IVUS).[@B13] Unique identifiers of Clinical Trial Registration-URL: <http://www.clinicaltrials.gov> were as follows: NCT01145079 for RESET, NCT01308281 for IVUS-XPL, and NCT01563952 for CTO-IVUS. Briefly, the RESET trial tested the non-inferiority of 3-month dual antiplatelet therapy following Endeavor sprint zotarolimus-eluting stent (Medtronic Inc., Santa Rosa, CA, USA) implantation, compared with 12-month dual antiplatelet therapy after implantation of another available DES. In the pre-specified long lesion subset of this study, 543 patients were randomly assigned to either IVUS- or angiography-guided DES implantation groups.[@B11] The IVUS-XPL trial investigated the usefulness of IVUS guidance during everolimus-eluting stent (Xience prime, Abbott Vascular, Santa Clara, CA, USA) implantation for long coronary lesions. A total of 1400 patients were randomly assigned to receive either IVUS- or angiography-guided stent implantation. The CTO-IVUS trial was undertaken to test the hypothesis that IVUS-guided CTO intervention would be superior to angiography-guided intervention. Four hundred two patients with CTO lesions were randomized to either IVUS- or angiography-guided intervention. Detailed protocols of these trials have been published previously.[@B10][@B11][@B12][@B13] The study protocols of these trials were approved by the Institutional Review Board of each participating institution, and written consent was obtained from all patients.

Of 1129 patients (333 women and 796 men) who underwent IVUS-guided intervention, women were older than men. In addition, there were significant differences in the frequencies of hypertension, dyslipidemia, current smoking, multi-vessel disease, and CTO lesions between women and men ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online). Accordingly, we performed propensity score matching to adjust for significant differences in clinical and angiographic characteristics in the women and men. After matching propensity scores for 333 women and 796 men, 333 matched pairs were selected for analysis.

Stent implantation
------------------

Next-generation DESs composed of everolimus-, zotarolimus-, and biolimus-eluting stents were implanted according to standard techniques. If a lesion could not be covered with a single stent, overlapping stents were used. Stent diameter and length were based on online IVUS measurements. Adjunct high-pressure dilation was performed at the discretion of the operators, based on the IVUS findings. Although IVUS could be performed at any step of DES implantation, post-intervention IVUS examination was mandatory.[@B11][@B12][@B13] One of two commercially available IVUS systems \[Atlantis or I-Lab (Boston Scientific Corp/SCIMED, Minneapolis, MN, USA) or Eagle Eye (Volcano Therapeutics, Rancho Cordova, CA, USA)\] was used.

Pre-PCI, all patients received at least 75 mg of aspirin. A loading dose of 300 mg of clopidogrel was administered at least 12 hours pre-PCI.[@B10][@B11][@B12][@B13] However, if the loading dose of clopidogrel was not administered 12 hours in advance, the patient received a 600 mg loading dose of clopidogrel in the catheterization laboratory prior to PCI.[@B10][@B11][@B12] Unfractionated heparin was administered to maintain an activated clotting time \>250 seconds. Use of glycoprotein IIb/IIIa inhibitors was left to the operator\'s discretion. After stent implantation, aspirin (100 mg, daily) was prescribed indefinitely; the duration of clopidogrel administration (75 mg, daily) depended on the randomized assignments in the RESET and IVUS-XPL trials.[@B11][@B12] In the CTO-IVUS trial, clopidogrel was used for at least 12 months.[@B13]

Anthropometry
-------------

At the time of the index procedure, height and body weight were measured using a digital scale in all patients. Body surface area (m^2^) was calculated using the Mosteller formula: √\[weight (kg)×height (cm)/3600\],[@B14] and body mass index (kg/m^2^) was calculated from the following formula: weight (kg)/\[height (m)\]^2^. Lean body mass (kg) was calculated using the James formula as follows: \[1.1×weight (kg)\]-{128×\[weight (kg)/height (cm)\]^2^} for men; \[1.07×weight (kg)\]-{148×\[weight (kg)/height (cm)\]^2^} for women.[@B15] Fat mass (kg) was calculated as lean body mass subtracted from body weight.

Angiographic and IVUS evaluation
--------------------------------

Angiographic and IVUS measurements were performed by analysts who were blinded to patient information and treatment assignments in an independent core laboratory at the Cardiovascular Research Center, Seoul, Korea. Quantitative coronary angiography analysis was performed using an off-line quantitative coronary angiographic system \[Cardiovascular Angiographic Analysis System (CAAS), Pie Medical Instruments, Maastricht, the Netherlands\]. Using a guiding catheter for magnification-calibration, the diameters of reference vessels (the average of the proximal and distal reference lumen diameters), the minimal luminal diameter, and the percent diameter stenosis were measured before and after DES implantation from diastolic frames in a single, matched view showing the smallest minimal luminal diameter.

Standardized planimetry of the lumen, stent, and vessel cross-sectional area was performed using planimetry software (Echoplaque, INDEC Systems, Santa Clara, CA, USA) in accordance with the IVUS guidelines of the American College of Cardiology.[@B16] Target lesions and both proximal and distal reference segments were assessed quantitatively. The post-intervention target lesion site was the image slice with the minimal lumen area (MLA). Proximal and distal reference segments were the most normal-looking segments within 5 mm proximal and distal to the target lesion.

Clinical outcomes and follow-up
-------------------------------

Post-PCI clinical assessments were performed in-hospital and at 1, 3, 6, and 12 months after discharge either by clinic visit or telephone interview. Clinical events were defined according to the Academic Research Consortium.[@B17] All deaths were considered cardiac deaths unless a definite non-cardiac cause could be established.[@B17] Target lesion-related myocardial infarction during the 1-year follow-up after hospital discharge was defined as the presence of clinical symptoms, electrocardiographic changes, or abnormal imaging findings of myocardial infarction, combined with an increase in the creatine kinase myocardial band fraction above the upper normal limits or an increase in troponin-T/troponin-I to greater than the 99th percentile of the upper normal limit. The territory of the myocardial infarction was supplied by the coronary artery containing the stented lesions.[@B12][@B17] Ischemia-driven target lesion revascularization was defined as a repeat PCI or bypass surgery of the target lesion with either of the following: 1) angiographic diameter stenosis ≥50% by quantitative coronary angiographic analysis with documented evidence of a positive stress test or 2) angiographic diameter stenosis ≥70% irrespective of documented evidence of a positive stress test.[@B17]

Statistical analysis
--------------------

Statistical analysis was performed using SPSS (version 18.0.0, SPSS Inc., Chicago, IL, USA) and R (version 2.8.0, R Foundation for Statistical Computing, Vienna, Austria) software. Propensity scores were estimated by fitting a logistic regression model using the following variables for women and men: age, hypertension, diabetes mellitus, dyslipidemia, current smoking, clinical presentation of acute myocardial infarction, angiographic multi-vessel disease, and lesions with CTO. Propensity score matching was performed using nearest neighbor matching without calipers. The Hansen and Bowers balance test *p*-value was 0.913, indicating good covariate balance. The C-statistic for the model was 0.567. Categorical variables are reported as numbers and percentages and were compared using the χ^2^ test or Fisher\'s exact test. Continuous variables are reported as means±standard deviations or medians (interquartile ranges). Differences between women and men were analyzed with Student\'s t test or the Mann-Whitney U test (if data were skewed), and those among the tertiles of patients\' height were analyzed by one-way analysis of variance or the Kruskal-Wallis test (if data were skewed). Adverse cardiac events at 12 months were compared using Cox\'s regression analysis stratified by enrolled trials. To determine independent predictors of adverse cardiac events, multivariable Cox\'s regression analysis with a stepwise method was performed and stratified by trials. Multivariable linear regression model using a stepwise method was applied to evaluate associations between anthropometric measurements and post-intervention MLA as assessed by IVUS. All *p*-values were two-sided, and a *p*-value \<0.05 was considered statistically significant.

RESULTS
=======

[Table 1](#T1){ref-type="table"} shows the clinical, procedural, and IVUS characteristics of the 666 patients who were matched by propensity scores. Compared to men, women were shorter in stature, weighed less, and had a smaller body surface area and lower lean body mass. Fat mass, however, was greater in women than in men. Body mass index was not different between women and men. Pre- and post-intervention reference vessel diameters by quantitative coronary angiographic analysis were smaller in women. In post-intervention IVUS analysis, MLA at the target lesions, as well as the lumen and external reference membrane area at the proximal and distal reference segments, were also significantly smaller in women than men.

PCI-related outcomes at 12 months are shown in [Table 2](#T2){ref-type="table"}. The incidence of adverse cardiac events, including cardiac death, target lesion-related myocardial infarction, and ischemia-driven target lesion revascularization, was not significantly different between women and men. The only significant predictor of adverse cardiac events was post-intervention MLA by IVUS \[hazard ratio (HR)=0.620, 95% confidence interval (CI)=0.423--0.909, *p*=0.014\], not female sex ([Supplementary Table 2](#S2){ref-type="supplementary-material"} and [3](#S3){ref-type="supplementary-material"}, only online).

[Fig. 1](#F1){ref-type="fig"} shows the associations between anthropometric measurements and post-intervention MLA evaluated by IVUS. While height, weight, body surface area, and lean body mass were significantly associated with post-intervention MLA, body mass index, and fat mass were not. The final multivariable linear regression analysis revealed that height (coefficient=0.041, 95% CI=0.025--0.057, *p*\<0.001) and CTO lesions (coefficient=-0.622, 95% CI=-1.077---0.167, *p*=0.008) were independently associated with post-intervention MLA as assessed by IVUS ([Supplementary Table 4](#S4){ref-type="supplementary-material"}, only online).

Clinical, procedural, and IVUS characteristics were compared according to tertiles of patient height, as shown in [Table 3](#T3){ref-type="table"}. Compared to the intermediate or high tertile patients, those in the low tertile of height were older and mostly female. Although their weight, body surface area, and lean body mass were the smallest, patients in the low tertile of height had a greater body mass index and fat mass than intermediate or high tertile patients. Post-intervention IVUS showed that the external elastic membrane and lumen area of the reference segment, as well as a MLA of target lesions, were smallest in patients in the low tertile of height. In an adjusted (age and sex) model, patients in the low tertile of height were at greater risk for adverse cardiac events at 12 months than those in the high tertile of height (HR=6.391, 95% CI=1.160--35.206, *p*=0.033) ([Fig. 2](#F2){ref-type="fig"}).

DISCUSSION
==========

In this IVUS study, sex was not independently associated with adverse cardiac events at 12 months after next-generation DES implantation for lesions with long stenosis or CTO. After next-generation DES implantation, the only significant predictor of adverse cardiac events was post-intervention MLA as evaluated by IVUS. Although women had smaller-sized reference vessels and post-intervention MLA than men, independent factors that affected post-intervention MLA were height and CTO lesions. Compared to patients in the high tertile of height, those in the low tertile of height were at greater risk of adverse cardiac events at 12 months.

Compared to men, women have smaller coronary arteries, regardless of body surface area.[@B6][@B7][@B8] These findings were based on angiography and autopsy,[@B6][@B7] and a previous IVUS study also demonstrated the presence of these characteristics, explaining the increased susceptibility of women to vessel occlusion.[@B8] However, despite the intrinsic effect of sex on coronary dimensions, little is known about sex differences in clinical outcomes, such as mortality or target lesion revascularization.[@B1][@B2][@B3] In the present study, we evaluated complex lesions based on the hypothesis that adverse cardiac events could differ significantly in incidence between males and females. Similar to previous studies,[@B6][@B7][@B8] we found that the vessel size of lesions with long stenosis or CTO was smaller in women than in men, and this feature of women was consequently associated with a smaller post-intervention MLA of the target lesion. However, sex was not associated with adverse clinical outcomes at 12 months post-intervention, and furthermore, its associations with post-intervention MLA were attenuated after adjusting for anthropometric variables. Accordingly, our results suggest that there is no sex-specific risk for procedural or clinical outcomes in coronary artery disease patients with complex lesions.

Previous cohort studies have consistently shown that overweight or obese patients with coronary artery disease exhibit better survival and lower cardiovascular events than normal weight patients.[@B18][@B19][@B20] However, it is controversial whether this obesity paradox is a real phenomenon, and the mechanisms responsible for this reversed association are still unknown.[@B18][@B19][@B20] Recently, an IVUS study suggested that a high body mass index was associated with a larger post-intervention stent area.[@B21] However, confounders were not fully adjusted for, and other anthropometric variables, with the exception of body mass index, were not evaluated.[@B21] In the present study, height, weight, body surface area, and lean body mass were associated with post-intervention MLA; body mass index and fat mass were not. Thus, tall and heavier patients might have a larger MLA after PCI than short and relatively thin patients, despite similar body mass indexes. Because height and weight contribute to body mass index in opposite ways, the lack of association between body mass index and post-intervention MLA suggests that a more important determinant of cardiovascular risk based on body mass index may be height, rather than weight.[@B22] In addition, the present study suggests that body mass index does not reflect obesity accurately, because it did not differentiate lean mass from body fat. This finding is consistent with the suggestion of a previous study,[@B18] and raises the question of whether body mass index is truly associated with cardiovascular events. Most previous studies have only used body mass index as a measure of obesity.[@B18]

Among the anthropometric variables measured in this study, height was most closely correlated to post-intervention MLA, and patients with a short stature tended to have more adverse events after PCI than taller patients. Although negative and even controversial studies have been published, a meta-analysis and two large population-based studies have shown an inverse association between height and coronary artery disease.[@B23][@B24][@B25] In the meta-analysis, the mean relative risk of cardiovascular morbidity and mortality was 1.46 in individuals in the shortest height category, compared to those in the tallest category, regardless of sex.[@B23] Although the mechanisms underlying this inverse association are unclear, a large study recently demonstrated a significant association between height-associated single nucleotide polymorphisms and coronary artery disease.[@B26] This link was partly explained by the association between shorter height and adverse lipid profiles.[@B26] In addition to biological mechanisms, the theory of coronary vessel caliber may explain the inverse association between height and coronary artery disease. In the Coronary Artery Surgery Study (CASS), surgical mortality was inversely associated with the average diameter of the grafted coronary arteries in both men and women.[@B27] Similarly, the present study showed a close relationship between height and post-intervention MLA that was a predictor for future adverse cardiac events.

Limitations
-----------

Our study may have been underpowered to compare the effects of sex and anthropometric measurements on PCI outcomes because of the small sample size. Especially, the events of cardiac death or myocardial infarction rarely occurred, thus limiting the effects of sex on these outcomes. Because patients were drawn from the Korean population, the findings may not be generalizable to other ethnic groups. However, similar tendencies to those observed in other ethnic groups regarding PCI outcomes and the obesity paradox have been reported in the Korean population.[@B28][@B29][@B30] Lean body mass was not actually measured. Finally, the included trials\' heterogeneity, such as inclusion/exclusion criteria and treatment strategies, may potentially affect the present results.

Conclusions
-----------

Sex was not found to be associated with post-intervention MLA as evaluated by IVUS and 12-month adverse cardiac events after next-generation DES implantation for lesions with long stenosis or CTO. However, height independently affected the post-intervention MLA of complex target lesions, and short stature may be associated with worse outcomes after PCI.
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![Associations among anthropometric measurements and post-intervention minimum lumen area (MLA) as evaluated by intravascular ultrasound. While height, weight, body surface area, and lean body mass were significantly associated with post-intervention MLA, body mass index and fat mass were not. Black dots indicate women and white dots indicate men.](ymj-58-296-g001){#F1}

![Adjusted event-free survival curve for the composite of cardiac death, target lesion--related myocardial infarction, and ischemia-driven target lesion revascularization, grouped by height tertile. The adjustment included age and sex, and the adjusted hazard ratio (HR) was relative to patients in the high tertile of height. CI, confidence interval.](ymj-58-296-g002){#F2}

###### Baseline, Procedural, and IVUS Characteristics by Sex

![](ymj-58-296-i001)

                                                    Women (n=333)      Men (n=333)       *p* value
  ------------------------------------------------- ------------------ ----------------- -----------
  Age (yrs)                                         67.2±8.0           66.4±8.0          0.222
  Height (cm)                                       154.2±5.3          166.8±6.1         \<0.001
  Weight (kg)                                       58.4±8.1           68.3±9.1          \<0.001
  Body surface area (m^2^)                          1.6±0.1            1.8±0.1           \<0.001
  Body mass index (kg/m^2^)                         24.6±3.3           24.5±2.7          0.667
  Lean body mass (kg)                               40.9±3.4           53.5±5.4          \<0.001
  Fat mass (kg)                                     17.5±5.3           14.8±4.1          \<0.001
  Hypertension                                      235 (70.6)         227 (68.2)        0.501
  Diabetes mellitus                                 126 (37.8)         123 (36.9)        0.810
  Dyslipidemia                                      247 (74.2)         237 (71.2)        0.385
  Current smoker                                    9 (2.7)            12 (3.6)          0.506
  Clinical diagnosis                                                                     0.689
   Stable angina                                    197 (59.2)         186 (55.9)        
   Unstable angina                                  110 (33.0)         119 (35.7)        
   Acute myocardial infarction                      26 (7.8)           28 (8.4)          
  Multi-vessel disease                              201 (60.4)         209 (62.8)        0.524
  Multi-vessel stent implantation                   88 (26.4)          80 (24.0)         0.475
  Chronic total occlusion                           37 (11.1)          40 (12.0)         0.716
  Duration of dual anti-platelet therapy (months)   12.0 (6.0, 12.0)   9.6 (6.0, 12.0)   0.626
  Coronary arteries                                                                      0.728
   Left anterior descending artery                  224 (67.3)         215 (64.6)        
   Left circumflex artery                           44 (13.2)          50 (15.0)         
   Right coronary artery                            65 (19.5)          68 (20.4)         
  Quantitative angiography analysis                                                      
   Pre-intervention                                                                      
    Reference vessel diameter (mm)                  2.8±0.4            2.9±0.5           0.038
    Minimum lumen diameter (mm)                     0.8±0.5            0.8±0.5           0.109
    Diameter stenosis (%)                           70.6±16.1          73.6±15.9         0.020
    Lesion length (mm)                              33.8±11.3          34.1±12.4         0.705
   Post-intervention                                                                     
    Reference vessel diameter (mm)                  2.9±0.4            3.0±0.5           0.008
    Minimum lumen diameter (mm)                     2.5±0.4            2.6±0.4           \<0.001
    Diameter stenosis (%)                           12.5±8.4           12.0±9.2          0.491
  Stent type                                                                             0.656
   Everolimus-eluting stent                         250 (75.1)         260 (78.1)        
   Zotarolimus-eluting stent                        63 (18.9)          55 (16.5)         
   Biolimus-eluting stent                           20 (6.0)           18 (5.4)          
  Stent overlap                                     112 (33.6)         107 (32.1)        0.680
  Stent diameter (mm)                               3.0±0.3            3.1±0.4           \<0.001
  Stent length (mm)                                 39.6±13.9          39.5±14.3         0.932
  Adjunct post-dilation                             235 (70.6)         225 (67.6)        0.402
  Final balloon size (mm)                           3.0±0.4            3.1±0.4           0.023
  Maximal inflation pressure (atm)                  17.3±3.9           16.3±3.8          0.009
  Post-intervention IVUS analysis                                                        
   Proximal reference segment EEM area (mm^2^)      15.9±4.4           18.2±5.3          \<0.001
   Proximal reference segment lumen area (mm^2^)    8.4±2.8            9.0±3.4           0.017
   Minimum lumen area (mm^2^)                       5.3±1.6            5.8±1.8           0.002
   Distal reference segment EEM area (mm^2^)        9.0±3.4            10.5±4.3          \<0.001
   Distal reference segment lumen area (mm^2^)      5.8±1.8            6.3±2.2           0.004

IVUS, intravascular ultrasound; EEM, external elastic membrane.

Data are presented as n (%), means±SD, or medians (interquartile ranges).

###### Adverse Cardiac Events at 12 Months
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                                                      Women (n=333)   Men (n=333)   Hazard ratio (95% confidence interval)   *p* value
  --------------------------------------------------- --------------- ------------- ---------------------------------------- -----------
  Adverse cardiac events                              8 (2.4)         8 (2.4)       1.039 (0.390--2.769)                     0.939
   Cardiac death^\*^                                  0 (0)           2 (0.6)       \-                                       0.499
   Target lesion--related myocardial infarction^\*^   0 (0)           2 (0.6)       \-                                       0.499
   Ischemia-driven target lesion revascularization    8 (2.4)         6 (1.8)       1.381 (0.479--3.982)                     0.551

^\*^Categorical variables were compared with Fisher\'s exact test (for 2-way comparisons).

###### Baseline, Procedural, and IVUS Characteristics According to Height Tertile
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                                                    Height             *p* value                            
  ------------------------------------------------- ------------------ ------------------ ----------------- ---------
  Age (yrs)                                         68.0±7.9           66.8±7.8           65.7±8.1          0.011
  Men                                               12 (5.6)           101 (45.9)         220 (94.4)        \<0.001
  Height (cm)                                       150.9±3.6          159.9±2.6          170.0±4.0         \<0.001
  Weight (kg)                                       57.1±7.8           61.9±8.0           70.6±8.8          \<0.001
  Body surface area (m^2^)                          1.5±0.1            1.7±0.1            1.8±0.1           \<0.001
  Body mass index (kg/m^2^)                         25.1±3.3           24.2±3.0           24.4±2.7          0.009
  Lean body mass (kg)                               39.8±3.1           46.0±4.8           55.1±5.2          \<0.001
  Fat mass (kg)                                     17.3±5.3           15.9±5.2           15.4±4.2          \<0.001
  Hypertension                                      156 (73.2)         150 (68.2)         156 (67.0)        0.319
  Diabetes mellitus                                 84 (39.4)          83 (37.7)          82 (35.2)         0.647
  Dyslipidemia                                      151 (70.9)         161 (73.2)         172 (73.8)        0.770
  Current smoker                                    6 (2.8)            5 (2.3)            10 (4.3)          0.443
  Acute myocardial infarction                       14 (6.6)           15 (6.8)           25 (10.7)         0.191
  Multi-vessel disease                              127 (59.6)         139 (63.2)         144 (61.8)        0.745
  Multi-vessel stent implantation                   56 (26.3)          57 (35.9)          55 (23.6)         0.776
  Chronic total occlusion                           28 (13.1)          24 (10.9)          25 (10.7)         0.680
  Duration of dual anti-platelet therapy (months)   12.0 (6.0, 12.0)   12.0 (6.0, 12.0)   6.0 (6.0, 12.0)   0.298
  Coronary arteries                                                                                         0.366
   Left anterior descending artery                  148 (69.5)         141 (64.1)         150 (64.4)        
   Left circumflex artery                           24 (11.3)          30 (13.6)          40 (17.2)         
   Right coronary artery                            41 (19.2)          49 (22.3)          43 (18.4)         
  Quantitative angiography analysis                                                                         
   Pre-intervention                                                                                         
    Reference vessel diameter (mm)                  2.8±0.4            2.8±0.5            2.9±0.5           0.328
    Minimum lumen diameter (mm)                     0.8±0.5            0.8±0.5            0.8±0.5           0.720
    Diameter stenosis (%)                           71.5±16.5          71.5±15.8          73.3±15.8         0.402
    Lesion length (mm)                              34.7±12.0          32.5±11.1          34.6±12.5         0.096
   Post-intervention                                                                                        
    Reference vessel diameter (mm)                  2.9±0.4            3.0±0.5            3.0±0.5           0.144
    Minimum lumen diameter (mm)                     2.5±0.3            2.6±0.4            2.6±0.4           0.005
    Diameter stenosis (%)                           12.4±8.9           11.4±8.6           12.9±8.9          0.195
  Stent type                                                                                                0.519
   Everolimus-eluting stent                         160 (75.1)         166 (75.5)         184 (79.0)        
   Zotarolimus-eluting stent                        37 (17.4)          44 (20.0)          37 (15.9)         
   Biolimus-eluting stent                           16 (7.5)           10 (4.5)           12 (5.2)          
  Stent overlap                                     76 (35.7)          67 (30.5)          76 (32.6)         0.509
  Stent diameter (mm)                               3.0±0.3            3.0±0.4            3.1±0.4           \<0.001
  Stent length (mm)                                 40.8±14.6          38.5±13.8          39.4±13.8         0.233
  Adjunct post-dilation                             142 (66.7)         161 (73.2)         157 (67.4)        0.269
  Final balloon size (mm)                           3.1±0.4            3.1±0.4            3.2±0.5           0.110
  Maximal inflation pressure (atm)                  17.3±4.0           16.6±4.1           16.5±3.5          0.176
  Post-intervention IVUS analysis                                                                           
   Proximal reference segment EEM area (mm^2^)      16.1±4.4           16.6±4.9           18.3±5.5          \<0.001
   Proximal reference segment lumen area (mm^2^)    8.3±2.7            8.6±2.9            9.2±3.6           0.022
   Minimum lumen area (mm^2^)                       5.2±1.5            5.6±1.8            5.9±1.8           \<0.001
   Distal reference segment EEM area (mm^2^)        8.7±3.0            9.6±4.0            10.9±4.4          \<0.001
   Distal reference segment lumen area (mm^2^)      5.6±1.6            6.0±2.0            6.4±2.3           \<0.001

IVUS, intravascular ultrasound; EEM, external elastic membrane.

Data are presented as n (%), means±SD, or medians (interquartile ranges).
